Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Emisphere Technologies, Inc.
Emisphere Technologies Announces the Launch of a Human Clinical Trial for Oral Parathyroid Hormone (PTH)
July 17th, 2008
Emisphere Technologies, Inc. (NASDAQ:EMIS) announced that Novartis Pharma AG has launched a Phase I study in postmenopausal women to determine the safety and tolerability of oral PTH134, a combination of human PTH-1-34 and the absorption enhancer 5-CNAC using Emisphere's proprietary Eligen(R) technology, for the treatment of postmenopausal osteoporosis. The study is designed to assess the bioavailability profile of increasing doses of PTH-1-34 combined with different amounts of 5-CNAC administered orally. The trial is being conducted in Switzerland and is estimated to yield first interpretable results by the end of the year. Osteoporosis is a disease associated with a...
Source: Women's Health Weekly (2008-07-17)
|
